Agilent Technologies Inc (A) CEO Sells $1,165,563.60 in Stock
Agilent Technologies Inc (NYSE:A) CEO Michael R. Mcmullen sold 15,923 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $73.20, for a total value of $1,165,563.60. Following the completion of the sale, the chief executive officer now owns 492,546 shares in the company, valued at approximately $36,054,367.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
A stock opened at $71.91 on Friday. The company has a market capitalization of $23.24 billion, a P/E ratio of 25.77, a price-to-earnings-growth ratio of 2.04 and a beta of 1.36. Agilent Technologies Inc has a 12-month low of $60.42 and a 12-month high of $75.11. The company has a current ratio of 3.29, a quick ratio of 2.74 and a debt-to-equity ratio of 0.39.
Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 19th. The medical research company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.07. The business had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.26 billion. Agilent Technologies had a return on equity of 19.84% and a net margin of 6.43%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. As a group, analysts forecast that Agilent Technologies Inc will post 3.04 EPS for the current year.
Agilent Technologies declared that its board has initiated a stock repurchase plan on Monday, November 19th that allows the company to repurchase $1.75 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 8.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
Several research firms recently weighed in on A. Deutsche Bank upped their price target on Agilent Technologies from $77.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, August 15th. ValuEngine downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Zacks Investment Research downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Morgan Stanley upped their price target on Agilent Technologies from $86.00 to $89.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 20th. Finally, Goldman Sachs Group upgraded Agilent Technologies from a “buy” rating to a “conviction-buy” rating in a research note on Monday, September 17th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $78.75.
A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Agilent Technologies by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 24,155,483 shares of the medical research company’s stock valued at $1,703,929,000 after acquiring an additional 194,607 shares in the last quarter. OppenheimerFunds Inc. lifted its position in Agilent Technologies by 12.5% in the 3rd quarter. OppenheimerFunds Inc. now owns 8,590,725 shares of the medical research company’s stock valued at $605,989,000 after acquiring an additional 954,104 shares in the last quarter. American Century Companies Inc. lifted its position in Agilent Technologies by 16.9% in the 3rd quarter. American Century Companies Inc. now owns 5,359,933 shares of the medical research company’s stock valued at $378,090,000 after acquiring an additional 774,771 shares in the last quarter. AQR Capital Management LLC lifted its position in Agilent Technologies by 1.2% in the 3rd quarter. AQR Capital Management LLC now owns 3,222,517 shares of the medical research company’s stock valued at $227,316,000 after acquiring an additional 37,709 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its position in Agilent Technologies by 6.6% in the 2nd quarter. Wells Fargo & Company MN now owns 2,984,214 shares of the medical research company’s stock valued at $184,544,000 after acquiring an additional 183,728 shares in the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Read More: Reverse Stock Split
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.